

Financial Tear Sheet

Corporate Profile

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's Disease (PD).

Stock Information

BCLI (Common Stock)	
Exchange	NASDAQ CM (US Dollar)
Price	\$3.19
Change (%)	▲ 0.03 (0.95%)
Volume	24,876
52 Week Low	\$2.88
Market Cap	\$60,108,296
Rolling EPS	-0.31
PE Ratio	0
Shares Outstanding	18,842,726
Data as of 02/16/18 3:59 p.m. ET	



Data provided by Nasdaq. Minimum 15 minutes delayed.

Latest News

February 7, 2018

BRAINSTORM'S NUROWN® PHASE 2 ALS CLINICAL TRIAL AND BIOMARKER ABSTRACTS ACCEPTED FOR PLATFORM PRESENTATIONS AT THE 70TH ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING IN LOS ANGELES, CALIFORNIA

February 6, 2018

BRAINSTORM CELL THERAPEUTICS TO PRESENT AT THE BIO CEO & INVESTOR CONFERENCE

February 5, 2018

BRAINSTORM CELL THERAPEUTICS APPOINTS SENIOR KITE EXECUTIVE, ANTHONY POLVERINO, PH.D., TO BOARD OF DIRECTORS

SEC Filings

Filing Date	Form
02/05/18	8-K
02/05/18	4
02/05/18	3
01/04/18	8-K

Upcoming Events

There are currently no events scheduled.

Primary IR Contact

Michael Rice
LifeSci Advisors LLC
E-mail: mrice@lifesciadvisors.com